Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026)
Nurix Therapeutics (NRIX) posted Liabilities and Shareholders Equity of $535.54 million for fiscal Q2 2026 (quarter ended May 31, 2026), down 9.5% from $591.56 million a year earlier and down 15.8% from the prior quarter.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
At the end of FY2025 (ended Nov 30, 2025), Nurix Therapeutics' Liabilities and Shareholders Equity came in at $688.14 million, up 2.8% from FY2024.
- Annual Liabilities and Shareholders Equity shows a five-year compound annual growth rate of 11.7% (FY2020 to FY2025).
- In prior fiscal years, Nurix Therapeutics' Liabilities and Shareholders Equity was $669.34 million in FY2024 (+88.2%), $355.6 million in FY2023 (-14.7%), $416.76 million in FY2022 (-12.6%) and $476.77 million in FY2021 (+20.3%).
- Quarterly Liabilities and Shareholders Equity has run from a low of $308.2 million in fiscal Q3 2023 to a high of $688.14 million in fiscal Q4 2025 over five years.
- On a year-over-year basis, Liabilities and Shareholders Equity increased in seven of the last eight quarters, with growth averaging 33.2%.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was fiscal Q1 2025, with growth of 96.7%; the weakest was fiscal Q3 2023, with a decline of 32.9%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior fiscal quarters was $636.13 million (Q1 2026), $688.14 million (Q4 2025) and $522.47 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Nurix Therapeutics | 2.46 Bn | 452.73 Mn | - | 535.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 535.54 Mn |
| Feb 28, 2026 | 636.13 Mn |
| Nov 30, 2025 | 688.14 Mn |
| Aug 31, 2025 | 522.47 Mn |
| May 31, 2025 | 591.56 Mn |
| Feb 28, 2025 | 615.04 Mn |
| Nov 30, 2024 | 669.34 Mn |
| Aug 31, 2024 | 513.60 Mn |
| May 31, 2024 | 511.03 Mn |
| Feb 29, 2024 | 312.67 Mn |
| Nov 30, 2023 | 355.60 Mn |
| Aug 31, 2023 | 308.20 Mn |
| May 31, 2023 | 350.62 Mn |
| Feb 28, 2023 | 370.15 Mn |
| Nov 30, 2022 | 416.76 Mn |
| Aug 31, 2022 | 459.34 Mn |
| May 31, 2022 | 394.31 Mn |
| Feb 28, 2022 | 437.72 Mn |
| Nov 30, 2021 | 476.77 Mn |
| Aug 31, 2021 | 493.07 Mn |
API Access
Nurix Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NRIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "NRIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NRIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();